Fuso Pharmaceutical Industries, Ltd. engages in the manufacture and sale of ethical pharmaceutical and medical equipment. It operates through the Pharmaceuticals and Real Estate divisions. The Pharmaceuticals division deals with the manufacture and sale of pharmaceutical products which mainly focus on prescription drugs, infusions, and artificial kidney dialysis solutions. The Real Estate division handles leasing of real estate properties. The company was founded on March 25, 1937 and is headquartered in Osaka, Japan.

Van Andel Institute provides biomedical research and education services. Its services include antibody production, spectral karyotyping, immunostaining and mouse modeling, animal imaging, computational biology, flow cytometry, germline modification and cytogenetics, mass spectrometry and proteomics, microarray technology, sequencing, vivarium, xenotransplantation and michigan animal consortium, as well as analytical, cellular and molecular microscopy services. The company was founded by Jay van Andel and Betty Van Andel in 1996 and is headquartered in Grand Rapids, MI.

Innovative Biologics (IBI) is an anti-infective small molecule drug discovery and development company targeting microbes producing pore-forming toxins, such as MRSA and Hepatitis C. Many pathogens utilize the formation of pores in the membranes of target cells in the process of infection. IBI has developed the CycloPlex™ platform to identify compounds which inhibit their action, based on blocking the target pore with molecules having the same symmetry as the pore itself, using ß-cyclodextrin as a scaffold.

The Group's principal activity is the provision of medical devices and research and developing bio pharmaceutical business. Its product includes Multimeters, Blood Pressure Manometers, Microwave Stimulators and Other Supplies.

Jellyfish Niangniang Marine Biotechnology Co., Ltd., established on 2016-07-13, The scope of business includes engaging in biotechnology,Construction Engineering Technology,Technology development in the field of beauty technology,Technical Services,technology transfer,technical consulting,Class I medical device,cosmetic,Jewelry,Flavors and Fragrances,Cleaning Products,hygiene products,Daily necessities,Clothing,Office Supplies,household appliances,Baby Products,Wholesale of electronic products,retail,e-commerce(Not to engage in financial business),hotel management,Real estate development and management,Pension institution business,Provide community care for the elderly,Home care and other community elderly care services,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

IQ Therapeutics' mission to become a leading biopharmaceutical company developing antibody based products for the prevention and treatment of infectious diseases and for biodefense. IQ Therapeutics has developed a proprietary technology for the generation of fully human antibodies from the blood of vaccinated or immunized donors. It is its philosophy that the most physiological origin for antibodies to be applied as therapeutic agent inside a human body is the human body itself. The human immune response is the basis for its technology and therefore they have termed it 'Cloning the Human Response TM'. Its aim is to apply this technology for the generation of protective antibodies which can serve as passive immunization to protect humans against infectious diseases and biodefense, thus providing 'instant immunity'.\nFor Anthrax infections they have developed human monoclonal antibodies directed against two components of the lethal toxin, PA and LF. Both antibodies fully protect animals when given before or after exposure. IQ has taken its unique anti-LF antibody as its lead product for drug development towards registration.\n'Cloning the Human ResponseTM' is also applied for various in-house developments to build a pipeline of potential novel antibody based drugs. Moreover, they offer the technology as service for third parties.

Intervet International BV engages in the manufacture and marketing of animal health products. It offers vaccines, anti-infectives, anti-parasitics, feed additives and products for fertility management. The firm products are used for treatment and care of poultry, pigs, cattle, sheep, goats, horses, fish, shrimp and companion animals. The company was founded by Wim Hendrix in 1949 and is headquartered in Boxmeer, the Netherlands.

US Agriculture LLC provides investment services. It operates and manage farmland assets and portfolios, develop and implement farmland investment strategies, underwrite and acquire farmland assets across a variety of regions and crop types, develop and implement efficient and effective reporting processes, design and implement investment policies, develop and implement asset allocation strategies, create and implement tools for market and asset targeting, and create and implement portfolio optimization tools and processes. The company was founded in 2015 and is headquartered in Indianapolis, IN.

ExThera Medical, based in Martinez, Calif., is targeting the clinical treatment of blood-borne diseases including viremia and bacteremia, as well as the removal of harmful substances present in banked human blood. For example, the treatment of bacteremia, caused by S. aureus or MRSA (Methicillin-Resistant S. aureus) usually relies heavily on antibiotics. ExThera Medical’s Seraph® device uses the affinity of bacteria to immobilized heparin within the device, to bind the pathogen and lower its concentration in the bloodstream. Naturally-occurring heparin is a well-known anticoagulant that has many other useful biological properties making Seraph® a ‘biomimetic therapeutic device’. It can be an adjunct to anti-infective drugs by reducing the load and duration of infection, potentially preventing complications and the systemic inflammatory response that leads to organ failure. When no effective drugs are available Seraph may help patients recover by supplementing their own immune systems.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

RxKinetix, Inc. develops new therapeutic drugs. The company uses proven pharmaceuticals and proprietary polymer-based drug delivery technologies and creates new drugs or enhances existing drugs. It also develops drugs for oral mucositis and other supportive care oncology conditions. RxKinetix was founded in 1996 and is located in Boulder, CO

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.